Unusual amino acids III. Asymmetric synthesis of 3-arylalanines
摘要:
21 (Z)-alpha-N-benzoylamino-beta-arylacrylic acids and their esters were prepared by known procedures and hydrogenated to the corresponding optically active alpha-benzoyl-beta-arylalanine derivatives with optical yields in the range of 82-95% ee using the cationic rhodium complex of ''PROPRAPHOS'' as the chiral catalyst No electronical influences of the substituents at the aryl moiety on the enantioselectivity were observed but a sterical one, proved by X-ray crystallographic analysis and computer-aided modellings. Deacylation of the hydrogenated spezies produced the hydrochlorides of the 3-arylalanines attended by a partial racemisation In this case the hydrogenation of urethane type protected dehydroaminoacid derivatives seems to be the alternative.
Provided herein are novel ligands and pharmaceutical compositions thereof which modulate IL-17A. Also provided are methods for preparing the IL-17A modulators. Such compounds may be useful in the treatment and/or prevention of, for example, inflammation, cancer or autoimmune disease.
Chiral Gating for Size- and Shape-Selective Asymmetric Catalysis
作者:Xiaowei Li、Yan Zhao
DOI:10.1021/jacs.9b06619
日期:2019.9.4
A poor or mediocre stereoselectivity is a key roadblock for a chiral cata-lyst to find practical adoptions. We report a facile method to create a tunable chiral space near a chiral catalyst to augment its selectivity. The space was created rationally through templated polymerization within cross-linked micelles, using readily available amino acid derivatives. It provided gated entrance of reactants
较差或中等的立体选择性是手性催化剂找到实际应用的主要障碍。我们报告了一种在手性催化剂附近创建可调手性空间以提高其选择性的简便方法。该空间是通过交联胶束内的模板聚合合理创造的,使用容易获得的氨基酸衍生物。它为反应物提供了进入催化剂的门控入口,使普通的脯氨酰胺能够以尺寸和形状选择性的方式以优异的产率和 ee 催化水中的羟醛缩合。
IL-17A MODULATORS AND USES THEREOF
申请人:Dice Alpha, Inc.
公开号:EP3921038A1
公开(公告)日:2021-12-15
[EN] IL-17A MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS D'IL-17A ET LEURS UTILISATIONS
申请人:DICE ALPHA INC
公开号:WO2020163554A1
公开(公告)日:2020-08-13
Provided herein are novel ligands and pharmaceutical compositions thereof which modulate IL-17A. Also provided are methods for preparing the IL-17A modulators. Such compounds may be useful in the treatment and/or prevention of, for example, inflammation, cancer or autoimmune disease.